BioSante Pharmaceuticals, Inc.
BioSante Pharmaceuticals Reports LibiGel® Status and Financial Results for 2008
Published in Drug Law Weekly, March 31st, 2009
“BioSante had an excellent year in 2008. Our new product development was led by the initiation of three LibiGel Phase III clinical trials,” said Stephen M. Simes, BioSante’s president and chief executive officer. “These clinical trials continue to enroll subjects and make progress. LibiGel is BioSante’s transdermal testosterone gel in late-stage development for the treatment of female sexual dysfunction (FSD) in menopausal women. LibiGel’s development continues under a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2009-03-31)
More Articles from Drug Law Weekly
- Allergies
Food Allergy Initiative to Partner With NYC Department of Health on Educational Poster for Restaurants Citywide - AllOne Health
AllOne Health to Provide Background Checks for Employers - Arbios Systems, Inc.
Arbios Announces Intent to File a Reorganization Plan - Cancer
U.S. Rep. Connolly, Inova Hospital Physicians, Public Health Groups Call for Congressional Action to Protect Kids From Tobacco - Cancer Vaccines
Medical Tourism - Choosing a Mexican Cancer Clinic - Colson Hicks Eidson
Miami Jury Awards More Than $38 Million in Tragic Pharmaceutical and Medical Negligence Case - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
